A method for establishing a PDPN rat model based on the analgesia hypothesis.

By employing a high-fat diet and rapid weight loss intervention, a PDPN rat model based on the 'pain caused by pain relief' hypothesis was constructed. This approach addresses the issues of low model success rate and poor stability in existing technologies, enabling the establishment of a highly efficient PDPN model suitable for basic research and clinical prevention and treatment.

CN123100558APending Publication Date: 2026-11-17GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610146377.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-10-15
Filing Date
2026-02-02
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing methods for establishing PDPN animal models suffer from problems such as poor model success rate, confusion with DPN, lack of clear model evaluation, and failure to clearly indicate the success rate of model establishment, which hinders the progress of PDPN research.

Method used

A novel rat model of PDPN based on the 'pain caused by weight loss' hypothesis was established. Through high-fat feeding, streptozotocin injection and rapid weight loss intervention, the excessive weight loss process of PDPN patients was simulated, and a stable rat model with obvious pathological characteristics of PDPN was constructed.

Benefits of technology

A 100% modeling success rate was achieved, and the constructed model has high stability and obvious pathological features, making it suitable for basic research and clinical prevention and treatment of PDPN.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100558A_ABST
    Figure CN123100558A_ABST
Patent Text Reader

Abstract

This invention relates to the field of biotechnology, specifically disclosing a method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis. The method includes: selecting healthy 8-week-old male SD rats, feeding them a high-fat diet freely for 4 weeks, then fasting them for 12 hours while allowing free access to water, followed by an intraperitoneal injection of 2% STZ (35 mg / kg). 72 hours after injection, the rats' random blood glucose levels at the tail tip are measured; rats with blood glucose levels ≥16.7 mmol / L are considered to have successfully established a diabetic model. After continuing the high-fat diet for 6 weeks, their mechanical pain threshold is measured; a decrease greater than 50% of the baseline threshold is considered a successful PDPN model. The rats are then randomly divided into a weight-loss intervention group and a control group using a random number method, and a rapid weight-loss intervention experiment is continued. PDPN model establishment is tested after 10 weeks. This novel PDPN rat model establishment method has advantages such as high model establishment rate, good stability, and obvious pathological characteristics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis. Background Technology

[0002] Diabetic peripheral neuropathy (DPN) is a common chronic complication of diabetes. Painful diabetic peripheral neuropathy (PDPN) accounts for approximately 25%–50% of all DPN patients. It is characterized by spontaneous pain, hyperalgesia, and neuropathy, and has widespread harmful effects. Its etiology and risk factors are unclear, and its pathogenesis is complex. Clinically, there is currently no ideal and effective treatment for intractable pain in PDPN. To conduct basic research and clinical prevention and treatment of PDPN, it is necessary to establish reliable, stable, and clinically relevant animal models of PDPN. There are currently many different methods for establishing PDPN animal models. For example, one method involves replicating the pathogenesis of PDPN, building upon a successfully established animal model of diabetes and waiting for PDPN to develop naturally.

[0003] However, these methods for establishing PDPN animal models still suffer from problems such as poor model success rate, confusion with DPN, lack of clear model evaluation, and failure to clearly indicate the success rate of model establishment, which hinders the progress of PDPN animal model research. Summary of the Invention

[0004] To address the aforementioned problems in existing methods for establishing PDPN rat models, this invention provides a novel method for establishing a PDPN rat model based on the "pain caused by pain relief" hypothesis. This novel method for establishing a PDPN rat model has advantages such as high model success rate, good stability, and obvious pathological characteristics.

[0005] To achieve the above-mentioned objectives, the present invention employs the following technical solution: a method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis, comprising the following steps: a. Select healthy 8-week-old male SD rats and feed them a high-fat diet with free access. After 4 weeks of high-fat diet with free access, the rats were fasted for 12 hours but allowed free access to water. They were then given an intraperitoneal injection of 2% streptozotocin at a dose of 35 mg / kg. 72 hours after the streptozotocin injection, the random blood glucose level at the tail tip of the rats was measured. Rats with a blood glucose level ≥16.7 mmol / L were considered to have successfully developed diabetes. b. After successful establishment of the diabetic model, continue with high-fat free-feeding; after 6 weeks of high-fat free-feeding, measure the mechanical pain threshold of the rats. Rats whose mechanical pain threshold decreases by more than 50% of the baseline threshold are considered to have successfully established PDPN; otherwise, they are considered to have failed to establish PDPN. c. The rats with established PDPN models, the rats without established PDPN models, and the rats in the blank control group were randomly divided into a weight loss intervention group and a weight loss control group using a random number method, and then a rapid weight loss intervention experiment was conducted. The feeding method for the weight loss intervention group included reducing the daily feed amount of the rats by 40% based on the amount required before weight loss. d. Ten weeks after the rapid weight loss intervention experiment, PDPN modeling was tested. Rats whose mechanical pain threshold decreased by more than 50% of the baseline pain threshold were considered to have successfully established the new PDPN rat model.

[0006] Preferably, in step a, the weight of the healthy 8-week-old male SD rat is 200±20g.

[0007] Preferably, the high-fat free-feeding method is as follows: providing rats with sufficient high-fat feed and allowing them to eat freely.

[0008] Preferably, the high-fat feed is a 60kcal high-fat rat diet, specifically the high-fat rat diet of Guangdong Provincial Medical Experimental Animal Center, production license number: Yue Si Zheng (2024) 05073.

[0009] Preferably, the 2% streptozotocin solution is prepared by dissolving streptozotocin powder in a citric acid-sodium citrate buffer solution in a certain proportion to obtain a 2% streptozotocin solution.

[0010] Preferably, the pH of the citric acid-sodium citrate buffer solution is 4.5.

[0011] In other embodiments, the feeding method of the weight loss intervention group also includes: reducing the amount of feed by 40% based on the daily feed required by the rats before weight loss, and simultaneously administering metformin solution by gavage daily.

[0012] Preferably, the metformin solution is administered by gavage: the required dose of metformin for rats is calculated by multiplying the human dose (1500mg / 70kg) by 6.3, and metformin hydrochloride tablets are dissolved in 2ml of water and then administered by gavage.

[0013] In other embodiments, rats were fasted for 12 hours but allowed free access to water, and then given an intraperitoneal injection of 2% streptozotocin at a dose of 30 mg / kg.

[0014] The beneficial effects of the novel PDPN rat model establishment method provided by this invention are as follows: a novel PDPN rat model can be successfully constructed through rapid weight loss intervention. The modeling success rate of the novel PDPN rat model constructed using this method is 100%. The constructed novel PDPN rat model has typical behavioral and pathological characteristics (including: the mechanical pain threshold after the weight loss intervention is more than 50% lower than the baseline threshold before the weight loss intervention; HE staining of the sciatic nerve: the overall structure of the sciatic nerve fibers in the non-model weight loss group is moderately to severe abnormal, the myelinated nerve fibers are sparsely arranged, the number of nerve fibers is sharply reduced, a large number of myelin sheath vacuolar degenerations are visible in the tissue, the myelin sheath gaps are enlarged, and demyelination is obvious; biological transmission electron microscopy: the myelinated nerve fibers in the non-model weight loss group are degenerated, the myelin sheath is wrinkled, locally tortuous and thickened, the sheath membrane is scattered and disintegrated, showing moderate to severe damage changes; the axon is moderately atrophied, and some internal axonal mesangiums are locally widened; microfilaments and microtubules are evenly distributed and abundant), with extremely high model stability, which can be well applied to basic research and clinical prevention and treatment of PDPN. Attached Figure Description

[0015] Figure 1 This is a bar chart comparing the body weight of rats before and after rapid weight loss intervention based on the "pain caused by relief" hypothesis in Example 2 of this invention.

[0016] Figure 2 This is a bar chart comparing blood glucose levels in rats before and after rapid weight loss intervention based on the "pain caused by weight loss" hypothesis in Example 2 of this invention.

[0017] Figure 3 This is a bar chart comparing the mechanical pain thresholds of rats before and after rapid weight loss intervention based on the "pain caused by pain reduction" hypothesis in Example 2 of this invention.

[0018] Figure 4 This is a bar chart comparing the MNCV and SNCV of different groups of rats after rapid weight loss intervention based on the "pain caused by weight loss" hypothesis in Example 2 of this invention; where A represents the MNCV comparison bar chart of rats and B represents the SNCV comparison bar chart of rats.

[0019] Figure 5 This is a schematic diagram illustrating the correlation between pain threshold and weight, MNCV and weight, and SNCV and weight in rapid weight loss intervention based on the "pain caused by pain" hypothesis in Embodiment 2 of the present invention; where A represents the correlation between pain threshold and weight, B represents the correlation between MNCV and weight, and C represents the correlation between SNCV and weight.

[0020] Figure 6 These are HE staining results of the sciatic nerve of rats in each group in Example 2 of the present invention; wherein, A1 is the blank control group, B1 is the healthy weight-loss group, C1 is the non-model control group, D1 is the non-model weight-loss group, E1 is the model control group, and F1 is the model weight-loss group.

[0021] Figure 7 These are images of the results of transmission electron microscopy observation of the sciatic nerve in each group of rats in Example 2 of this invention; where A1 is the blank control group, B1 is the healthy sciatic nerve reduction group, C1 is the non-model control group, D1 is the non-model sciatic nerve reduction group, E1 is the model control group, and F1 is the model sciatic nerve reduction group; MF is myelinated nerve fiber, MS is myelin sheath, A is axon, MT is mitochondria, UF is unmyelinated nerve fiber, thin arrows indicate degeneration and dissociation of myelin sheath lamellar structure, and thick arrows indicate local widening of the internal axonal mesangium (IM).

[0022] Figure 8 These are immunohistochemical results of subcutaneous nerve fibers in the foot of rats in each group in Example 2 of this invention; where A1 is the blank control group, B1 is the healthy weight-loss group, C1 is the non-model control group, D1 is the non-model weight-loss group, E1 is the model control group, and F1 is the model weight-loss group.

[0023] Figure 9 This is a flowchart of the method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis in Embodiment 1 of the present invention. Detailed Implementation

[0024] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0025] In the process of pursuing this application, the applicant discovered that a significant proportion of PDPN patients had previously employed aggressive weight loss methods, including excessive dieting, high-intensity exercise, and inappropriate use of hypoglycemic weight loss drugs.

[0026] Based on the traditional Chinese medicine view that "illness arises from overuse" and the clinical characteristics of PDPN patients, the applicant proposed the "pain caused by wasting" hypothesis: that is, excessive weight loss by diabetic patients in order to control blood sugar and weight, resulting in a significant weight loss in a short period of time, may be one of the important factors that induce PDPN.

[0027] Based on this hypothesis of "pain caused by weight loss," the applicant has provided a novel method for establishing a PDPN rat model. This animal modeling method constructs a novel PDPN rat model through rapid weight loss intervention, and has advantages such as high model success rate, good stability, and obvious pathological characteristics.

[0028] Example 1: 1) Materials 47 SPF-grade healthy 8-week-old SD rats, with a body mass of (200±20) g, were purchased from the Animal Experiment Center of the Higher Education Mega Center Campus of Guangzhou University of Chinese Medicine, with the experimental animal production license number: SYXK (Yue) 2023-0347. The rats were housed in the Animal Experiment Center of the Sanyuanli Campus of Guangzhou University of Chinese Medicine, in an SPF-grade environment, at a temperature of (22±2)°C, a humidity of (60±10)%, and with a 12h / 12h light-dark cycle.

[0029] High-fat diet: The high-fat diet is a 60% kcal high-fat rodent diet, purchased from Guangdong Provincial Medical Laboratory Animal Center, with the production license number: Yue Si Zheng (2024) 05073.

[0030] 2% Streptozotocin (STZ) solution: STZ powder is dissolved in a citric acid-sodium citrate buffer solution in proportion to obtain a 2% STZ solution. The pH of the citric acid-sodium citrate buffer solution is 4.5.

[0031] The 50% paw withdrawal threshold (i.e., mechanical pain threshold) is measured using Von Frey filaments combined with the "Up & Down" method for rodent mechanical pain threshold, to quantify the pain sensitivity of experimental animals to mechanical stimuli.

[0032] Specifically, first select a Von Frey filament with an initial force value, stimulate the plantar of the animal (for example, vertically and gently press the central area of the plantar of the animal's hind paw), and observe whether there is a paw withdrawal or escape response. Then, adjust the force value of the next filament according to the response: if there is a paw withdrawal or escape response, use a filament with a smaller force value (Down); if there is no paw withdrawal or escape response, use a filament with a larger force value (Up). Continue the stimulation and observation until a consecutive "response-no response" pattern switch occurs (for example, 6 response transitions are obtained). Finally, calculate the 50% paw withdrawal threshold according to the response sequence and the standard table.

[0033] Rapid weight loss intervention: Based on the daily required feed amount of the rats before weight loss, the feeding amount is reduced by 40%.

[0034] 2) Method for establishing a novel PDPN rat model based on the "pain caused by elimination" hypothesis a. Select an appropriate number of healthy 8-week-old male SD rats as the experimental group, and feed them with a high-fat diet ad libitum for 4 weeks to induce insulin resistance.

[0035] After 4 weeks of high-fat, ad libitum feeding, rats were fasted but allowed free access to water for 12 hours, followed by intraperitoneal injection of 2% streptozotocin (STZ) solution at a dose of 35 mg / kg (in some embodiments, the dose of STZ solution may be 30 mg / kg). 72 hours after STZ injection, the random blood glucose level at the tail tip of the rats was measured. Rats with a blood glucose level ≥16.7 mmol / L were considered to have successfully developed diabetes.

[0036] A blank control group was set up, with rats fed a standard diet on an ad libitum basis for 4 weeks. After 4 weeks of ad libitum feeding, the rats in the blank control group were fasted but allowed free access to water for 12 hours. They were then administered a single intraperitoneal injection of 0.1 mmol / L citrate-sodium citrate solution at the same dosage. 72 hours after administration of the citrate-sodium citrate solution, the random blood glucose level at the tail tip of the rats in the blank control group was measured.

[0037] b. After the experimental group rats with successful diabetes modeling continued to be fed a high-fat, free-range diet for 6 weeks, their mechanical pain threshold was measured. Among them, the experimental group rats whose mechanical pain threshold decreased by more than 50% of the baseline threshold were considered to have successfully developed PDPN, otherwise they were considered to have failed to develop PDPN.

[0038] In addition, the rats in the blank control group were also fed with regular feed on an ad libitum basis, and after 6 weeks of feeding, the mechanical pain threshold of the rats in the blank control group was measured in the same way.

[0039] c. The rats with established PDPN model, rats without established PDPN model, and rats in the blank control group were randomly re-divided into a weight loss intervention group and a weight loss control group using the random number method, and a rapid weight loss intervention experiment was conducted.

[0040] The weight loss intervention group included: non-model weight loss group composed of PDPN non-model rats assigned to the weight loss intervention group; model weight loss group composed of PDPN model rats assigned to the weight loss intervention group; and healthy weight loss group composed of blank control group rats assigned to the weight loss intervention group. The weight loss control group included: model control group composed of PDPN model rats assigned to the weight loss control group; non-model control group composed of PDPN non-model rats assigned to the weight loss control group; and blank control group composed of blank control group rats assigned to the weight loss control group.

[0041] In this rapid weight loss intervention experiment, the weight loss intervention group underwent a rapid weight loss intervention (i.e., the aforementioned 40% dietary restriction) to simulate a real clinical scenario. The weight loss control group was fed a regular diet with free access and was given an equal volume of water by gavage.

[0042] d. Ten weeks after the rapid weight loss intervention experiment, the rats in the weight loss intervention group were tested for PDPN modeling. When the mechanical pain threshold of the rat decreased by more than 50% of the baseline pain threshold, the rat was determined to be a rat that had successfully established the new PDPN rat model.

[0043] In other embodiments, the feeding method for the weight loss intervention group also includes: reducing the amount of feed by 40% based on the daily feed required by the rats before weight loss, while simultaneously administering metformin solution by gavage daily.

[0044] Specifically, the metformin solution gavage refers to: calculating the required metformin dose for rats by multiplying the human dose (1500mg / 70kg) by 6.3, dissolving metformin hydrochloride tablets in 2ml of water, and then administering the solution by gavage.

[0045] Example 2: 1) Comparison between traditional PDPN animal model construction methods and the construction method of this invention: After 4 weeks of high-fat diet feeding, combined with intraperitoneal injection of low-dose STZ solution, 35 rats were subjected to diabetes modeling 6 weeks later. After 6 weeks, the rats were automatically identified as PDPN models. The mechanical pain threshold was considered to have decreased by more than 50% of the baseline value.

[0046] Of the 35 rats, 3 died unexpectedly due to insufficient ventilation in the cage, and 1 died from severe fighting. After calculating the model success rate based on the time of death, a total of 18 rats spontaneously became PDPN models, while 14 rats did not. Therefore, the model success rate of this traditional DPN modeling method is 18 / 32 = 56.25%.

[0047] Rats that spontaneously develop PDPN under traditional PDPN modeling methods are considered PDPN-established rats, while rats that do not spontaneously develop PDPN are considered PDPN-non-established rats. For example... Figure 1 , Figure 2 as well as Figure 3 As shown, after a further 10-week rapid weight loss intervention (i.e., step c) in the PDPN non-modeling weight loss group, all 7 rats that originally did not become PDPN models using the traditional PDPN modeling method became PDPN models after the weight loss intervention (i.e., the mechanical pain threshold after the weight loss intervention was greater than 50% lower than the baseline threshold before the weight loss intervention), achieving a modeling rate of 100%. Therefore, the success rate of the novel PDPN rat model construction method based on the "pain caused by pain relief" hypothesis in Example 1 is significantly improved compared to the traditional PDPN modeling method.

[0048] 2) Correlation between pain threshold, MNCV, SNCV and body weight after weight loss intervention After the rapid weight loss intervention, the motor nerve conduction velocity (MNCV) of both the non-modeled and modeled weight loss groups was significantly lower than that of the corresponding non-modeled and modeled control groups. P 0.05). There was no statistically significant difference in MNCV between the healthy weight-loss group and the blank control group. P 0.05).

[0049] The sensory nerve conduction velocity (SNCV) of the non-scaled reduction group and the scaled reduction group was statistically significant compared with that of the healthy reduction group and the blank control group. P 0.05), but compared with its corresponding non-model control group and model control group, there was no statistically significant difference ( P (0.05), but SNCV shows a downward trend.

[0050] After weight loss intervention, body weight and mechanical pain threshold did not meet the normality requirement, while MNCV and SNCV met the normality requirement. Spearman's rank correlation coefficient was used to analyze the correlation between mechanical pain threshold, MNCV, SNCV and body weight in rats after the weight loss intervention. The mechanical pain threshold and body weight in rats showed a positive correlation. P The correlation coefficient was 0.745, indicating a high correlation; MNCV in rats showed a positive correlation with body weight. P The correlation coefficient was 0.728, indicating a high correlation; rat SNCV showed a positive correlation with body weight. P The correlation coefficient was 0.609, indicating a moderate correlation (0.001).

[0051] 3) Comparison of nerve conduction velocities in rats after weight loss intervention: Slowed nerve conduction velocity and reduced action potential amplitude are typical manifestations of diabetic peripheral nerve injury, primarily reflecting the function of large-diameter nerve fibers and myelin sheaths, and can be used to quantitatively assess the degree of nerve damage. This invention evaluates and quantifies nerve conduction velocity in rats by measuring the conduction velocity of the sciatic nerve.

[0052] like Figure 4 and Figure 5As shown, after the weight loss intervention, the MNCV of both the non-modeled and modeled weight loss groups was significantly lower than that of the corresponding non-modeled and modeled control groups (P < 0.05). 0.05). The non-model-forming weight loss group and the model-forming weight loss group showed significantly lower SNCVs compared to the healthy weight loss group and the blank control group, but there was no statistically significant difference compared to their corresponding non-model-forming control group and model-forming control group (P < 0.05). (0.05), but SNCV shows a clear downward trend, which may be related to insufficient sample size.

[0053] Further correlation analysis between nerve conduction velocity and body weight indicated a positive correlation between MNCV, SNCV and body weight in rats (P < 0.05). The correlation coefficients (r) were 0.728 and 0.609, respectively, indicating that the lower the rat's body weight, the lower the level of nerve conduction velocity. These results suggest that rapid weight loss intervention can significantly reduce nerve conduction velocity in diabetic rats, indicating significant impairment of nerve function.

[0054] 4) Comparison of HE staining results of sciatic nerve in rats of different groups like Figure 6 As shown, in the blank control group A1, the overall structure of the myelinated sciatic nerve fibers was normal, with clear and neat arrangement. The myelin sheath was tightly packed, structurally intact, abundant, and uniformly stained. Blue Schwann cell nuclei were scattered at the edge of the myelin sheath, and no obvious myelin degeneration was observed. Compared with the blank control group, the healthy reduction group B1 showed mild nerve damage. The overall structure of the sciatic nerve fibers was slightly abnormal, with clear and neat arrangement of the myelinated nerve fibers. A small number of nerve fiber breaks, axonal swelling, and myelin sheath destruction were visible. In the non-reduction control group C1 and the completed reduction control group E1, the overall structure of the sciatic nerve fibers was mild to moderately abnormal. The sciatic nerve fibers were clear and neatly arranged, with a small number of nerve fiber breaks, axonal swelling, and myelin sheath destruction visible in the tissue. In the non-reduction group D1 and the completed reduction group F1, the overall structure of the sciatic nerve fibers was moderate to severe abnormal. The myelinated nerve fibers were sparsely arranged, the number of nerve fibers was sharply reduced, and a large number of myelin sheath vacuolar degenerations, increased myelin sheath gaps, and obvious demyelination were visible in the tissue.

[0055] 5) Results of transmission electron microscopy observation of the sciatic nerve in rats of each group like Figure 7As shown, in the blank control group A1, the myelinated sciatic nerve fibers were structurally intact, with axons tightly wrapped by concentric lamellar myelin sheaths, uniform interlamellar spacing, and clear boundaries. The axonal outline was full, with regularly arranged microtubules and microfilaments visible within. Mitochondria were visible within the axons and in the cytoplasm of Schwann cells, appearing as round or short rods with intact double-membrane structures and uniformly distributed cristae. In the unmyelinated nerve fibers, multiple axons were wrapped by the same Schwann cell, and no myelin sheath formation was observed. In the healthy depletion group B1, the myelinated nerve fibers were structurally intact, with mild myelin sheath damage and uneven thickness. The lamellar structures were arranged in parallel, with a small portion showing mild damage. The axonal outline was full, with regularly arranged microtubules and microfilaments visible within, and the matrix was slightly sparse. The mitochondrial structure was normal; the microfilaments and microtubules were evenly distributed. In the non-modeled control group C1, the myelinated nerve fibers exhibited regular myelin sheath morphology and a relatively good structure. The myelin sheath lamellar structure was compact, with some local structures appearing scattered and blurred, indicating mild to moderate damage. Most axons showed no abnormalities, with some exhibiting slight atrophy and localized slight depressions. Microfilaments and microtubules were abundant. In the non-modeled reduction group D1, the myelinated nerve fibers showed degeneration, myelin sheath shrinkage, localized tortuosity and thickening, and sheath fragmentation, indicating moderate to severe damage. Axons showed moderate atrophy, and some internal axonal mesangiums were locally widened. Microfilaments and microtubules were evenly distributed and abundant. In the modeled control group E1, the myelinated nerve fibers showed degeneration of the myelin sheath structure, sheath fragmentation, and some visible breaks and defects, indicating moderate damage. Axons showed atrophy, and the internal axonal mesangiums were locally widened. Microfilaments and microtubules were evenly distributed, and a small number of unmyelinated nerve fibers were visible in the field of view. The myelinated nerve fibers of the F1 degenerative group showed degeneration, myelin sheath shrinkage, uneven thickness, fragmentation and breakage of the sheath membrane, and tortuous and thickened lamellar structure of the myelin sheath, showing severe damage; axons were severely atrophied, some axonal membrane structures were blurred, and the matrix was slightly sparse; the number of mitochondria was small; microfilaments and microtubules were unevenly distributed, and some areas were slightly sparse.

[0056] 6) Immunohistochemical results of subcutaneous nerve fibers in the foot of rats in each group like Figure 8As shown, the distribution characteristics of nerve fibers labeled with PGP9.5 are as follows: In the blank control group A1, the plantar epidermal nerve fibers showed clear course, orderly arrangement, uniform thickness, and intact structure with no obvious damage. In other experimental groups (healthy weight loss group B1, non-model control group C1, non-model weight loss group D1, model control group E1, and model weight loss group F1), subcutaneous nerve fibers exhibited varying degrees of morphological abnormalities, including shortening, disordered course, uneven thickness, and compromised fiber integrity. Among these, the nerve fibers in the healthy weight loss group B1 were slightly shortened, indicating milder damage. The degree of nerve fiber damage in the non-model weight loss group D1 and the model weight loss group F1 was significantly higher than that in their respective non-model control group C1 and model control group E1. The intraepidermal nerve fiber density (IENFD) in the non-model weight loss group D1 and the model weight loss group F1 was lower than that in the non-model control group C1 and the model control group E1, but the difference was not statistically significant. P 0.05).

[0057] The above experimental results all confirm that the PDPN rat model obtained by the novel PDPN rat model based on the "pain caused by pain" hypothesis provided by this invention has advantages such as high model success rate, good stability and obvious pathological characteristics.

[0058] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis, characterized in that: Includes the following steps: a. Select healthy 8-week-old male SD rats and feed them a high-fat diet with free access. After 4 weeks of high-fat diet with free access, the rats were fasted for 12 hours but allowed free access to water. They were then given an intraperitoneal injection of 2% streptozotocin at a dose of 35 mg / kg. 72 hours after the streptozotocin injection, the random blood glucose level at the tail tip of the rats was measured. Rats with a blood glucose level ≥16.7 mmol / L were considered to have successfully developed diabetes. b. After successful establishment of the diabetic model, continue with high-fat free-feeding; after 6 weeks of high-fat free-feeding, measure the mechanical pain threshold of the rats. Rats whose mechanical pain threshold decreases by more than 50% of the baseline threshold are considered to have successfully established PDPN; otherwise, they are considered to have failed to establish PDPN. c. The rats with established PDPN models, the rats without established PDPN models, and the rats in the blank control group were randomly divided into a weight loss intervention group and a weight loss control group using a random number method, and then a rapid weight loss intervention experiment was conducted. The feeding method for the weight loss intervention group included reducing the daily feed amount of the rats by 40% based on the amount required before weight loss. d. Ten weeks after the rapid weight loss intervention experiment, PDPN modeling was tested. Rats whose mechanical pain threshold decreased by more than 50% of the baseline pain threshold were considered to have successfully established the new PDPN rat model.

2. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 1, characterized in that: The weight of the healthy 8-week-old male SD rats was 200±20g.

3. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 1, characterized in that: The high-fat free-feeding method is as follows: provide rats with sufficient high-fat feed and allow them to eat freely.

4. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 3, characterized in that: The high-fat feed is a 60kcal high-fat rat diet.

5. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 1, characterized in that: The streptozotocin powder was dissolved in a citrate-sodium citrate buffer solution in a certain proportion to obtain a 2% streptozotocin solution.

6. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 5, characterized in that: The pH of the citric acid-sodium citrate buffer solution is 4.

5.

7. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 1, characterized in that: The mechanical pain threshold of the rats was measured using the rodent mechanical pain threshold "Up & Down" method.

8. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 1, characterized in that, The feeding method for the weight loss intervention group also included: reducing the daily feed amount of the rats by 40% based on the daily feed amount required before weight loss, and simultaneously administering metformin solution by gavage daily.

9. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 8, characterized in that, The metformin solution was administered via gavage: the required dose of metformin for rats was calculated by multiplying the human dose by 6.3, and metformin hydrochloride tablets were dissolved in 2 ml of water and then administered via gavage; the human dose was 1500 mg / 70 kg.

10. The method for establishing a novel PDPN rat model based on the "pain caused by pain relief" hypothesis as described in claim 1, characterized in that, The rats were fasted for 12 hours but allowed free access to water, and then administered 2% streptozotocin via intraperitoneal injection at a dose of 30 mg / kg.